Ignite Creation Date:
2024-05-06 @ 7:55 PM
Last Modification Date:
2024-10-26 @ 3:16 PM
Study NCT ID:
NCT06181656
Status:
RECRUITING
Last Update Posted:
2024-05-23
First Post:
2023-12-13
Brief Title:
Serologic Response to Pneumococcal Vaccination Among Esophageal Cancer Patients With High Grade Lymphopenia After Chemoradiation
Sponsor:
MD Anderson Cancer Center
Organization:
MD Anderson Cancer Center
Study Overview
Official Title:
Serologic Response to Pneumococcal Vaccination Among Esophageal Cancer Patients With High Grade Lymphopenia After Chemoradiation
Status:
RECRUITING
Status Verified Date:
2024-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To learn how radiation treatment may affect your responses to vaccines against pneumonia
Detailed Description:
Primary Objectives
- Determine the impact of Grade IV radiation-induced lymphopenia on serologic responses to pneumococcal vaccination
Secondary Objectives
Determine the impact of chemoradiation on serologic responses to pneumococcal vaccination
Determine the impact of radiation modality on serologic responses to pneumococcal vaccination
Determine the impact of radiation modality on systemic immunity
Determine the incidence of pneumonia among patients treated with a pneumococcal vaccine
Determine the impact of radiation modality on pathologic response
Determine the impact of radiation modality on intratumoral immunity
Determine the relationship between changes in systemic and intratumoral immunity and clinical outcomes ie incidence of pneumonia and pathologic response
Determine the impact of tumor histology on serologic responses to pneumococcal vaccination
- Determine the impact of Grade IV radiation-induced lymphopenia on serologic responses to pneumococcal vaccination
Secondary Objectives
Determine the impact of chemoradiation on serologic responses to pneumococcal vaccination
Determine the impact of radiation modality on serologic responses to pneumococcal vaccination
Determine the impact of radiation modality on systemic immunity
Determine the incidence of pneumonia among patients treated with a pneumococcal vaccine
Determine the impact of radiation modality on pathologic response
Determine the impact of radiation modality on intratumoral immunity
Determine the relationship between changes in systemic and intratumoral immunity and clinical outcomes ie incidence of pneumonia and pathologic response
Determine the impact of tumor histology on serologic responses to pneumococcal vaccination
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| NCI-2023-10646 | OTHER | NCI-CTRP Clinical Registry | None |